Tenderwize
Back to tender search

Medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2027 · 221 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Cinnarizin und Dimenhydrinat (ATC: N07CA22)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

20 / 100

Risk factors

No estimated value or framework maximum is provided, making it impossible to assess potential revenue. The contract is...

The buyer explicitly reserves the right to terminate the agreement if exclusive contracts for the same active ingredien...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of finished medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)
  • Conclusion of non-exclusive discount agreements under §130a Abs. 8 SGB V
Show full summary

This notice announces a non-exclusive discount agreement (Rabattvertrag) under §130a Abs. 8 SGB V for finished medicinal products containing the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22). It follows an open-house model, allowing any qualified pharmaceutical company to conclude a standard contract at any time. The contract runs for a maximum of 24 months from the earliest start date (01.06.2025) until 31.05.2027. The notice explicitly states it is not a public procurement under GWB but is published for transparency. No estimated value or framework maximum value is provided. The submission process is unclear: structured data indicates electronic submission is not allowed, but the XML notice mentions the possibility of submitting electronically signed documents via email.

Risks

No estimated value or framework maximum is provided, making it impossible to assess potential revenue. The contract is...

The buyer explicitly reserves the right to terminate the agreement if exclusive contracts for the same active ingredien...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies
  • Contract must be signed and returned to the contact address

Administrative

  • Must request and submit participation documents fully completed and signed

Requirements may be incomplete.

Buyer

Location

Magdeburg, DEU

Buyer profile

Open profile

Identifier

DE258393558

Activity

Health

Lots (1)

LOT-0001

Medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)

Non-exclusive discount agreements for finished medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22) under an open-house model. Any qualified pharmaceutical company can join at any time. No exclusivity. Contract duration: maximum 24 months, ending 31.05.2027 irrespective of start date. Early termination possible if the health insurance fund (AOK Sachsen-Anhalt) tenders exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Location

DEE03, Germany

Duration

2 YEAR

Category

Pharmaceutical products

Deadline

Deadline Mar 30, 2027

Procurement Details

Publication date
09 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
234181-2025

Documents (1)

Similar tenders